Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II trial of R-DA-EDOCH versus R-CHOP as first-line therapy for selected advanced de novo diffuse large B-cell lymphoma
ChiCTR1900028209Phase 2Not yet recruiting
- Sponsor
- The Affiliated Hospital of Jiangnan University
- Start
- Jan 2020
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of rituximab, etoposide, pegylated liposomal doxorubicin, vindesine, cyclophosphamide and 2 more in diffuse large B-cell lymphoma (DLBCL) (2 arms), sponsored by The Affiliated Hospital of Jiangnan University. Primary endpoints: Progression-free survival and Overall survival. Planned start Jan 2020; status: not yet recruiting.
02
Drugs
rituximabetoposidepegylated liposomal doxorubicinvindesinecyclophosphamide
03
Conditions
diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on ChiCTR1900028209.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR1900028209.